21 Pediatric Brain Tumor 1 1 0 24 24 17 http://clinicaltrials.dfhcc.harvard.edu/trials/17 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma cells become more like normal cells, and grow and spread more slowly. Giving combination chemotherapy with or without isotretinoin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which treatment regimen is more effective in treating young patients with neuroblastoma. PURPOSE: This phase III trial is comparing different regimens of combination chemotherapy and surgery with or without isotretinoin to see how well they work in treating young patients with neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 3 48 http://clinicaltrials.dfhcc.harvard.edu/trials/48 Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. It is not yet known which combination chemotherapy regimen is more effective when given before a peripheral stem cell transplant in treating supratentorial primitive neuroectodermal tumors or medulloblastoma. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given before a peripheral stem cell transplant in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma . Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 3 257 http://clinicaltrials.dfhcc.harvard.edu/trials/257 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known which regimen of myeloablation chemotherapy is more effective for patients with high-risk neuroblastoma undergoing a peripheral blood stem cell transplant. PURPOSE: This randomized phase III trial is comparing two different myeloablation therapies followed by a stem cell transplant in treating young patients with high-risk neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 3 305 http://clinicaltrials.dfhcc.harvard.edu/trials/305 Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without monoclonal antibody therapy, interleukin-2, and sargramostim following stem cell transplantation in treating neuroblastoma. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with or without monoclonal antibody, interleukin-2, and sargramostim following stem cell transplantation in treating patients who have neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 3 340 http://clinicaltrials.dfhcc.harvard.edu/trials/340 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma RATIONALE: Drugs used in chemotherapy, work in different ways to stop tumor cells from dividing so they stop growing or die. Steroid therapy decreases inflammation. Combining chemotherapy and steroid therapy with immunoglobulin may be effective in treating abnormal muscle movement associated with neuroblastoma. PURPOSE: This randomized phase II trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements associated with neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 3 1362 http://clinicaltrials.dfhcc.harvard.edu/trials/1362 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase III clinical trial is studying how well combination chemotherapy and surgery work in treating young patients with Wilms tumor. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 3 116 http://clinicaltrials.dfhcc.harvard.edu/trials/116 Iodine I 131 Metaiodobenzylguanidine, Combination Chemotherapy, and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell or Bone Marrow Transplant for Relapsed or Refractory Neuroblastoma RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine, may carry radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as carboplatin, etoposide, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. An autologous peripheral stem cell or bone marrow transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Giving iodine I 131 metaiodobenzylguanidine and combination chemotherapy with an autologous peripheral stem cell or bone marrow transplant may allow more chemotherapy to be given so that more tumor cells are killed. Giving radiation therapy after an autologous peripheral stem cell or bone marrow transplant may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well giving iodine I 131 metaiodobenzylguanidine together with combination chemotherapy and radiation therapy works in treating patients who are undergoing an autologous peripheral stem cell or bone marrow transplant for relapsed or refractory neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 2 292 http://clinicaltrials.dfhcc.harvard.edu/trials/292 RAD001 for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas. Additionally, the safety of RAD001 will be studied. RAD001 is a drug that may act directly on tumor cells by inhibiting tumor cell growth and proliferation. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 2 601 http://clinicaltrials.dfhcc.harvard.edu/trials/601 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Treatment Overview This phase II study will evaluate the activity of sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas that have the potential to cause significant morbidity. The following disease strata will be studied: Stratum 1: Progressive plexiform neurofibroma(s) that have the potential to cause significant morbidity. The endpoint will be time to tumor progression based on volumetric tumor measurements. Stratum 2: Plexiform neurofibromas without documented radiographic progression at trial entry. The endpoint will be radiographic response. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 2 164 http://clinicaltrials.dfhcc.harvard.edu/trials/164 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 1 584 http://clinicaltrials.dfhcc.harvard.edu/trials/584 Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma RATIONALE: Drugs used in chemotherapy, such as fenretinide LXS, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide LXS in treating patients with recurrent, refractory, or persistent neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 1 598 http://clinicaltrials.dfhcc.harvard.edu/trials/598 Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor Phase 1 6 http://clinicaltrials.dfhcc.harvard.edu/trials/6 A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors In spite of numerous advances in neuroimaging techniques, the diagnosis of pediatric brain tumors relies on the pathologic evaluation of material obtained at the time of the initial operation. While 18F-FDG-positron emission tomography (PET) helps identify higher-grade lesions due to their increased glucose metabolism, the high tracer uptake of the normal adjacent brains makes this modality of limited value. Fluorine-18 fluorothymidine (FLT) is a new imaging agent that has two significant advantages in the imaging of CNS tumors. First, this agent detects cellular proliferation directly, and second, the normal brain does not take up the agent, making a positive area(s) easy to identify. Before embarking on a large pediatric disease stratified assessment of FLT imaging in pediatric neurooncology patients, the investigators are proposing a limited patient pilot study to evaluate the biodistribution, dosimetry and specificity of this compound when compared to immunohistochemical assessment of mitotic activity in newly diagnosed patients undergoing surgical resection. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor N/A 25 http://clinicaltrials.dfhcc.harvard.edu/trials/25 Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor N/A 114 http://clinicaltrials.dfhcc.harvard.edu/trials/114 Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET) RATIONALE: Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function in young patients with cancer. PURPOSE: This clinical trial is studying neuropsychological and behavioral testing in young patients with medulloblastoma or supratentorial primitive neuroectodermal tumor (PNET). Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 121 http://clinicaltrials.dfhcc.harvard.edu/trials/121 Evaluating Dactinomycin and Vincristine in Young Patients With Cancer RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how dactinomycin and vincristine affect the body and how patients will respond to treatment. PURPOSE: This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors N/A 171 http://clinicaltrials.dfhcc.harvard.edu/trials/171 Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging RATIONALE: Gathering information over time from imaging and laboratory tests of infants with adrenal masses may help doctors learn more about the disease and plan the best treatment. PURPOSE: This natural history study is collecting health information about infants with adrenal masses found on prenatal and/or neonatal imaging. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor N/A 212 http://clinicaltrials.dfhcc.harvard.edu/trials/212 Study of Late-Occurring Complications in Childhood Cancer Survivors RATIONALE: A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. PURPOSE: This clinical trial is studying cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. Recruiting 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related N/A 281 http://clinicaltrials.dfhcc.harvard.edu/trials/281 Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer RATIONALE: Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor N/A 357 http://clinicaltrials.dfhcc.harvard.edu/trials/357 Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors RATIONALE: Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future. PURPOSE: The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor N/A 1190 http://clinicaltrials.dfhcc.harvard.edu/trials/1190 Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-Cis-Retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cisretinoic acid has on children and adolescents with recurrent/refractory brain tumors Find out how the body uses 13-cisretinoic acid by studying the your blood levels and proteins in the blood that break down the 13-cisretinoic acid Determine how well 13-cisretinoic acid penetrates into the spinal fluid. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer 1243 http://clinicaltrials.dfhcc.harvard.edu/trials/1243 PEG-Interferon Alfa-2b in Treating Young Patients With Unresectable Plexiform Neurofibromas Associated With Neurofibromatosis Type 1 RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells. It may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well PEG-interferon alfa-2b works in treating patients with unresectable plexiform neurofibromas associated with neurofibromatosis type 1. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer 1246 http://clinicaltrials.dfhcc.harvard.edu/trials/1246 A Study of Aprepitant (MK0869) and Fosaprepitant (MK0517) in Pediatric Patients Receiving Chemotherapy This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy induced nausea and vomiting in pediatric patients from 6 months to 17 years of age. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 22 Pediatric Solid Tumors http://clinicaltrials.dfhcc.harvard.edu/diagnoses/22-pediatric-solid-tumors 20 Pediatric Blood Related http://clinicaltrials.dfhcc.harvard.edu/diagnoses/20-pediatric-blood-related 1412 http://clinicaltrials.dfhcc.harvard.edu/trials/1412 Bevacizumab, Cyclophosphamide, and Zoledronic Acid in Treating Patients With Recurrent or Refractory High-Risk Neuroblastoma RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zoledronic acid may stop the growth of tumor cells in bone. Giving bevacizumab together with cyclophosphamide and zoledronic acid may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving bevacizumab together with cyclophosphamide and zoledronic acid in treating patients with recurrent or refractory high-risk neuroblastoma. Recruiting 21 Pediatric Brain Tumor http://clinicaltrials.dfhcc.harvard.edu/diagnoses/21-pediatric-brain-tumor 2 Brain/Neuro Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/2-brain-neuro-cancer